Free Daily Podcast Summary
The Psychedelic News Feed: Daily Summaries Delivered
by Psychedelic Alpha
The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 days ago21 min
Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including:Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy)California carves out $4.7M for psychedelic researchThe DEA again moves to schedule 5 tryptaminesThe PATH Caucus publishes its RFI white paperStanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF)Read more:Psychedelic Bulletin 232: Oregon Backpedals Psilocybin Fee Hike; DEA Again Moves to Schedule 5 TryptaminesThe Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.Send us your questions and comments at pod@psychedelicalpha.com Read more and join our newsletter at https://psychedelicalpha.comFollow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
- 2 weeks ago18 min
Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefingA commentary published by top FDA staff outlining a model for psychedelic drug developmentNew Zealand’s approval of two psychiatrists to prescribe MDMAAnd many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.Read more:No Questions Asked: FDA’s Psychedelics Public Hearing‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine WorkshopPsychedelic Bulletin 231Field Notes #5: 'Psychedelics Week' in Washington D.C.Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSDDefinium Notches Second Positive Phase 3 in Generalised Anxiety DisorderThe Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.Send us your questions and comments at pod@psychedelicalpha.com Read more and join our newsletter at https://psychedelicalpha.comFollow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
About The Psychedelic News Feed
The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Psychedelic News Feed in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Psychedelic News Feed daily summary?
It's a free AI-powered email that summarizes new episodes of The Psychedelic News Feed as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Psychedelic News Feed podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Psychedelic News Feed product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Psychedelic Alpha.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Psychedelic News Feed release new episodes?
The Psychedelic News Feed publishes biweekly. Our AI generates a summary within hours of each new episode.
What topics does The Psychedelic News Feed cover?
The Psychedelic News Feed covers topics including News, Business, Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Psychedelic News Feed summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.